COVID-19 vaccine developer CureVac shares more than triple after U.S. debut

Shares of German biotechnology firm CureVac BV soared as much as 222% after their Nasdaq debut on Friday, in the first stock market opening of a company developing a potential vaccine to combat the novel coronavirus.

from Top Business News- News18.com https://ift.tt/3aynndV